Saturday 17 October 2026
Export NRC’s income statement to Excel — free account
National Research Corporation
NRC Healthcare Health Information Services
National Research Corporation’s revenue for fiscal 2025 (year ended December 2025) was $137.4 million, down 3.96% from fiscal 2024. In the quarter to June 2026, revenue grew 3.98%, EPS fell 3,091.5%, free cash flow grew 101.5% and total debt rose 11.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.
20.15
0.96
−4.55%
Follow NRC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
86.28 | 42.95 | 37.15 | 18.12 |
+8 more quarters Free account |
P/S ratio |
3.39 | 2.67 | 3.06 | 2.03 | |
P/FCF ratio |
21.94 | 21.24 | 26.69 | 24.34 | |
P/Operating CF |
342.52 | 51.55 | 58.52 | 20.55 | |
P/B ratio |
72.49 | 27.43 | 30.03 | 19.76 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.98 | 3.19 | 3.57 | 2.56 | |
EV/EBITDA |
23.74 | 15.81 | 16.20 | 10.31 | |
EV/Operating CF |
18.89 | 16.37 | 18.56 | 13.90 | |
EV/FCF |
25.76 | 25.34 | 31.19 | 30.69 | |
Quick Ratio |
0.48 | 0.36 | 0.43 | 0.39 | |
Current Ratio |
0.65 | 0.52 | 0.55 | 0.53 | |
Net Debt/EBITDA |
(75.86) | 9.20 | 10.36 | 7.41 | |
Debt/Assets |
63.17% | 55.01% | 55.62% | 56.02% | |
Debt/Equity |
13.13 | 5.48 | 5.36 | 5.31 | |
Asset Turnover |
1.01 | 1.03 | 1.03 | 1.04 | |
Operating CF/Net income |
(0.42) | 2.23 | 4.82 | 3.34 | |
Capex/Depreciation |
(0.62) | (0.84) | (0.52) | (1.61) | |
Interest Coverage |
(2.45) | 4.44 | 3.41 | 5.30 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
64.83% | 38.56% | 41.04% | 35.46% | |
Intangible Assets out of Total Assets |
0.50 | 0.51 | 0.51 | 0.50 | |
Share Based Compensation of Revenue |
20.83% | 4.62% | 5.42% | 2.67% | |
Graham Net Nets |
(0.22) | (0.27) | (0.24) | (0.36) | |
Graham Number |
1.29 | 2.35 | 2.67 | 3.20 | |
Earnings Yield |
1.16% | 2.33% | 2.69% | 5.52% | |
Free Cash Flow Yield |
4.56% | 4.71% | 3.75% | 4.11% | |
Revenue per Share |
1.61 | 1.60 | 1.57 | 1.56 | |
Operating CF per Share |
0.06 | 0.33 | 0.32 | 0.62 | |
Capex per Share |
(0.06) | (0.08) | (0.05) | (0.16) | |
Free Cash Flow per Share |
0.00 | 0.25 | 0.27 | 0.46 | |
Cash per Share |
0.15 | 0.12 | 0.18 | 0.10 | |
Shareholders Equity per Share |
0.30 | 0.62 | 0.63 | 0.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.30 | 0.62 | 0.63 | 0.65 | |
Free Cash Flow |
0.06 | 5.35 | 6.06 | 10.18 | |
Working Capital |
(12.21) | (18.49) | (16.41) | (18.16) | |
Capital Expenditures |
(1.32) | (1.83) | (1.12) | (3.59) | |
Net Current Asset Value |
(106.80) | (101.08) | (100.68) | (101.00) | |
EV/EBIT |
37.82 | 22.57 | 21.74 | 12.96 | |
Capex to Sales |
0.04 | 0.05 | 0.03 | 0.10 | |
Price to Operating Income |
32.21 | 18.92 | 18.60 | 10.28 | |
| Other line items | |||||
Average Receivables |
13.25 | 11.39 | 11.42 | 12.23 | |
Average Payables |
1.25 | 2.13 | 1.18 | 1.84 | |
Average Assets |
138.77 | 134.87 | 133.71 | 133.76 | |
Average Common Equity |
13.94 | 21.58 | 22.64 | 24.47 |
Columns are period end dates